Nyxoah S.A. (NYXH)
- Previous Close
8.61 - Open
8.83 - Bid --
- Ask --
- Day's Range
8.43 - 8.83 - 52 Week Range
4.00 - 20.00 - Volume
10,640 - Avg. Volume
11,964 - Market Cap (intraday)
289.764M - Beta (5Y Monthly) 0.60
- PE Ratio (TTM)
-- - EPS (TTM)
-1.65 - Earnings Date Nov 5, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
17.06
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
www.nyxoah.comRecent News: NYXH
View MorePerformance Overview: NYXH
Trailing total returns as of 9/20/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NYXH
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NYXH
View MoreValuation Measures
Market Cap
291.07M
Enterprise Value
218.79M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
47.16
Price/Book (mrq)
2.21
Enterprise Value/Revenue
41.09
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-20.36%
Return on Equity (ttm)
-36.94%
Revenue (ttm)
4.79M
Net Income Avi to Common (ttm)
-43.53M
Diluted EPS (ttm)
-1.65
Balance Sheet and Cash Flow
Total Cash (mrq)
77.78M
Total Debt/Equity (mrq)
10.61%
Levered Free Cash Flow (ttm)
-38M